Bioinformatic analyses revealed underlying biological functions correlated with oxaliplatin responsiveness
Tóm tắt
Colorectal cancer is one of the most common cancers worldwide. Surgery is usually the primary treatment for colon cancers that have not spread to distant sites. However, chemotherapy may be considered after surgery to eliminate remaining cancer cells or in case the cancer has a high risk of recurrence. Oxaliplatin is often used in combination regimens such as FOLFOX, CapeOX, and FOLFOXIRI because of the cost-effectiveness of adjuvant treatment for patients and also the good tolerability profile. However, some patients show resistance to oxaliplatin which causes poor treatment outcomes. Most colon cancer studies focused on treatments and patient survival. Some studies focused on genetic associations of specific genes. However, pathway and network analyses of oxaliplatin resistance in colon cancer cells using gene expression patterns are still lacking. We performed a microarray analysis and found that endothelin-1 (EDN1), dishevelled segment polarity protein (DV1), toll-like receptor 5(TLR5), mitogen-activated protein kinase 3 (MAP2K3), phosphatidylinositol-4,5-bisphosphate 3-kinase, and catalytic subunit beta (PIK3CB) were closely related to responsiveness to oxaliplatin treatment. Furthermore, we found that the signal transduction, melanogenesis, and toll-like receptor signaling pathways might be involved in oxaliplatin-resistant colon cancer. These genes and pathways might be potential targets for improving oxaliplatin treatment in colon cancer patients.
Tài liệu tham khảo
Binefa G et al. Colorectal cancer: from prevention to personalized medicine. World J Gastroenterol. 2014;20(22):6786–808.
Ruers T, Bleichrodt RP. Treatment of liver metastases, an update on the possibilities and results. Eur J Cancer. 2002;38(7):1023–33.
Scheele J, Stangl R, Altendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg. 1990;77(11):1241–6.
Gunderson LL et al. Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010;28(2):264–71.
O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst. 2004;96(19):1420–5.
Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet, 1995. 345(8955): p. 939–44.
Twelves C et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005;352(26):2696–704.
Porschen R et al. Fluorouracil plus leucovorin as effective adjuvant chemotherapy in curatively resected stage III colon cancer: results of the trial adjCCA-01. J Clin Oncol. 2001;19(6):1787–94.
Andre T et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343–51.
Haller DG et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol. 2011;29(11):1465–71.
Aballea S et al. An economic evaluation of oxaliplatin for the adjuvant treatment of colon cancer in the United Kingdom (UK). Eur J Cancer. 2007;43(11):1687–93.
Attard CL et al. Cost-effectiveness of oxaliplatin in the adjuvant treatment of colon cancer in Canada. Curr Oncol. 2010;17(1):17–24.
Shiroiwa T et al. Cost-effectiveness of adjuvant FOLFOX therapy for stage III colon cancer in Japan based on the MOSAIC trial. Value Health. 2012;15(2):255–60.
Lairson DR et al. Cost-utility analysis of chemotherapy regimens in elderly patients with stage III colon cancer. Pharmacoeconomics. 2014;32(10):1005–13.
Markman M. Toxicities of the platinum antineoplastic agents. Expert Opin Drug Saf. 2003;2(6):597–607.
de Gramont A et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18(16):2938–47.
Di Francia R et al. Current strategies to minimize toxicity of oxaliplatin: selection of pharmacogenomic panel tests. Anti-cancer Drugs. 2013;24(10):1069–78.
Lecomte T et al. Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin Cancer Res. 2006;12(10):3050–6.
Gamelin L et al. Predictive factors of oxaliplatin neurotoxicity: the involvement of the oxalate outcome pathway. Clin Cancer Res. 2007;13(21):6359–68.
Ramanathan RK et al. Incidence and evolution of oxaliplatin-induced peripheral sensory neuropathy in diabetic patients with colorectal cancer: a pooled analysis of three phase III studies. Ann Oncol. 2010;21(4):754–8.
Kweekel DM, Gelderblom H, Guchelaar HJ. Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treat Rev. 2005;31(2):90–105.
Brookes AJ. The essence of SNPs. Gene. 1999;234(2):177–86.
Wei JC et al. Association study of polymorphisms rs4552569 and rs17095830 and the risk of ankylosing spondylitis in a Taiwanese population. PLoS One. 2013;8(1), e52801.
Yen JH et al. A polymorphism of ORAI1 rs7135617, is associated with susceptibility to rheumatoid arthritis. Mediat Inflamm. 2014;2014:834831.
Chang WC. Pharmacogenomics in personalized medicine and drug metabolism. Biomed Res Int. 2014;2014:897963.
Chang HW et al. The importance of integrating SNP and cheminformatics resources to pharmacogenomics. Curr Drug Metab. 2012;13(7):991–9.
Ruzzo A et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol. 2007;25(10):1247–54.
Park DJ et al. A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res. 2001;61(24):8654–8.
Stoehlmacher J et al. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer. 2004;91(2):344–54.
Braun MS et al. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J Clin Oncol. 2008;26(16):2690–8.
Monzo M et al. Single nucleotide polymorphisms in nucleotide excision repair genes XPA, XPD, XPG and ERCC1 in advanced colorectal cancer patients treated with first-line oxaliplatin/fluoropyrimidine. Oncology. 2007;72(5–6):364–70.
Viguier J et al. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res. 2005;11(17):6212–7.
Martinez-Balibrea E et al. Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer. Eur J Cancer. 2008;44(9):1229–37.
Puyo S et al. Gene expression signature predicting high-grade prostate cancer responses to oxaliplatin. Mol Pharmacol. 2012;82(6):1205–16.
Aubert J et al. Determination of the differentially expressed genes in microarray experiments using local FDR. BMC Bioinf. 2004;5:125.
de Gramont A et al. From chemotherapy to targeted therapy in adjuvant treatment for stage III colon cancer. Semin Oncol. 2011;38(4):521–32.
Wolpin BM, Mayer RJ. Systemic treatment of colorectal cancer. Gastroenterology. 2008;134(5):1296–310.
Lee ME et al. Functional analysis of the endothelin-1 gene promoter. Evidence for an endothelial cell-specific cis-acting sequence. J Biol Chem. 1990;265(18):10446–50.
Simonson MS. Endothelins: multifunctional renal peptides. Physiol Rev. 1993;73(2):375–411.
Rubanyi GM, Polokoff MA. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev. 1994;46(3):325–415.
Nelson J et al. The endothelin axis: emerging role in cancer. Nat Rev Cancer. 2003;3(2):110–6.
Eberl LP et al. Endothelin receptor blockade potentiates FasL-induced apoptosis in rat colon carcinoma cells. Int J Cancer. 2000;86(2):182–7.
Asham E et al. Increased endothelin-1 in colorectal cancer and reduction of tumour growth by ET(A) receptor antagonism. Br J Cancer. 2001;85(11):1759–63.
Takai D et al. Silencing of HTR1B and reduced expression of EDN1 in human lung cancers, revealed by methylation-sensitive representational difference analysis. Oncogene. 2001;20(51):7505–13.
Kozminski KG et al. A motility in the eukaryotic flagellum unrelated to flagellar beating. Proc Natl Acad Sci U S A. 1993;90(12):5519–23.
Rosenbaum JL, Witman GB. Intraflagellar transport. Nat Rev Mol Cell Biol. 2002;3(11):813–25.
Bhogaraju S et al. Molecular basis of tubulin transport within the cilium by IFT74 and IFT81. Science. 2013;341(6149):1009–12.
Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol. 2004;4(7):499–511.
Kawai T, Akira S. TLR signaling. Cell Death Differ. 2006;13(5):816–25.
Gewirtz AT et al. Cutting edge: bacterial flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expression. J Immunol. 2001;167(4):1882–5.
Rhee SH et al. Pathophysiological role of Toll-like receptor 5 engagement by bacterial flagellin in colonic inflammation. Proc Natl Acad Sci U S A. 2005;102(38):13610–5.
Kaisho T, Akira S. Pleiotropic function of Toll-like receptors. Microbes Infect. 2004;6(15):1388–94.
Pimentel-Nunes P et al. Decreased Toll-interacting protein and peroxisome proliferator-activated receptor gamma are associated with increased expression of Toll-like receptors in colon carcinogenesis. J Clin Pathol. 2012;65(4):302–8.
Xu G et al. MicroRNA-21 promotes hepatocellular carcinoma HepG2 cell proliferation through repression of mitogen-activated protein kinase-kinase 3. BMC Cancer. 2013;13:469.
MacNeil AJ et al. MAPK kinase 3 is a tumor suppressor with reduced copy number in breast cancer. Cancer Res. 2014;74(1):162–72.
Jia M et al. Proteome profiling of immortalization-to-senescence transition of human breast epithelial cells identified MAP2K3 as a senescence-promoting protein which is downregulated in human breast cancer. Proteomics Clin Appl. 2010;4(10–11):816–28.
Galan-Moya EM et al. Balance between MKK6 and MKK3 mediates p38 MAPK associated resistance to cisplatin in NSCLC. PLoS One. 2011;6(12), e28406.
Le Stunff C et al. Association analysis indicates that a variant GATA-binding site in the PIK3CB promoter is a Cis-acting expression quantitative trait locus for this gene and attenuates insulin resistance in obese children. Diabetes. 2008;57(2):494–502.